In recent years, the therapeutic potential of estrogen receptor beta (ERβ) in breast cancer, prostate cancer, lung cancer, the nervous system, and bone tissue has been revealed, and this target has attracted more and more attention [1,2,3,4]. The gene discussed is ESR2; the disease is prostate carcinoma.